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Abstract
Conformationally restricted bicyclic amines have been found to be very useful scaffolds 
in medicinal chemistry. Examples can be found in the chemical literature for the 
application of conformationally restricted diamines. These molecules can be used as 
enzyme inhibitors or GPCR ligands. Conformational restriction can improve affinity and 
selectivity toward receptors. The stereochemical diversity-oriented approach is a method 
that explores stereochemical effects in small molecule ligands for proteins. It is an 
effective strategy when the bioactive conformation of a ligand and the pharmacophore of 
the binding site are unknown. These concepts are applied in the design the target 
[4.2.1]di-azabicyclic compounds. The nitrogen atoms can be functionalized differently if 
they are protected appropriately to provide increased structural diversity. The shift of the 
nitrogen atom along the four-atom bridge provides the opportunity to scan a broad region 
of space. The modified approach of the synthesis toward these targets utilizes selective 
oxidation/reduction and stereochemically well-defined reactions to modify the functional 
groups and stereochemistry in the compound. This paper describes the research done so 
far to obtain these conformationally restricted diamine targets and the characterization of
the novel intermediates.
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Introduction
There are several techniques that a medicinal chemist can apply when optimizing 
a lead compound. The flexibility of a compound may affect its affinity toward a target 
protein. Conformational restriction can be utilized to promote the rigidity of a molecule 
which may result in improved receptor selectivity, increased potency, and increased 
metabolic stability. Approaches to conformational restriction include incorporation of 
steric bulk, unsaturation, or cyclization.^ Designing a small molecule to act as an 
enzyme inhibitor or G-protein coupled receptor ligand requires a methodical approach. 
The stereochemical diversity-oriented approach explores altering stereochemistry and 
positions of atoms within compounds that may alter biological activity, target selectivity 
and pharmaceutical properties. The target molecules presented in this paper are 
conformationally restricted diamines.
Conformationally restricted diamines have been reported as very useful molecules 
in medicinal chemistry. Epibatidine, (2), is a potent bicyclic ligand for the acetylcholine 
receptor that binds to a4(32 receptors in rat brain in the picomolar range. Its high toxicity 
prevents it from being used clinically which led to the synthesis of [2.2.1] diamine 
scaffold analogues, 3 and 4, by Bunnelle and coworkers.[2] The compounds were tested 
to displace [3H]-cysteine from rat brain membranes. When compared to a flexible 
compound like nicotine (1) the conformationally restricted bicyclic diamine structures 
showed higher affinity and selectivity. These bicyclic diamine scaffolds proved to be 
useful in making potent nAChR ligands that rival the affinity of epibatidine.
3
Figure 1: Nicotine (1, Ki = 0.94 nM), epibatidine (2, Ki = 0.047 nM), and 
conformationally restricted bicyclic diamine analogues 3 (Ki = 0.018 nM) and 4 (Ki = 
0.10nM).[2]
Epibatidine is a non-selective nAChR ligand that has influenced research toward 
other nAChR subtypes. Mortell and coworkers utilize [3.3.0] bicyclic diamines as 
nAChR ligands. These rigid structures provide an opportunity to explore the changing of 
functional groups in a specific position and its effect on activity. Compound 5 was a lead 
nAChR ligand with selectivity toward rat a7 receptors over other subtypes. Compound 6 
was developed by combining elements from epibatidine and 5. It was found to be more 
effective as an agonist than its parent compound 5.[3] This study shows how different 
functionalization in a specific orientation in space can be useful in improving the activity 
of a compound.
Figure 2: Parent compound 5 (Ki = 11 nM) and its analogue 6 (Ki = 3.6 nM).[3]
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A method to improve understanding of the effects of stereochemistry is the 
stereochemical diversity-oriented approach. This involves the synthesis of templates that 
are stereoisomers. It is an effective strategy in developing protein ligands, when neither 
the bioactive conformation nor the pharmacophore are k n o w n . W a t a n a b e  and 
coworkers developed conformationally restricted analogues of histamine which 
introduced chiral cis- and /ram-cyclopropane. Through stereoselective synthesis, sixteen 
unique compounds (Figure 3) were made and tested for H3 and H4 receptor antagonism. 
It was discovered that 12a had good antagonist activity to both H3 (Ki = 8.4 nM) and H4 
(Ki = 7.6 nM) receptors. Compound 14a showed high selectivity for H3 receptors (Ki = 
3.6 nM) while 11a was selective toward H4 receptors (Ki = 118 nM). Compound 11a 
was the first H4 subtype selective antagonist designed using this style of approach. 
This study illustrates the importance of conformational restriction, exploration of 
functionality on nitrogen atoms, and the exploration of stereochemistry through a wide 
array of compounds to obtain active and selective molecules.
Figure 3: H3/H4 receptor ligands developed from stereochemical diversity-oriented 
approach.[4]
NH
R
7 a, b: n = 1
8 a, b: n = 2
9 a, b: n = 1
10 a, b: n = 2
11 a, b: n = 1 13 a, b: n = 1
12 a, b:n = 2 14 a, b: n = 2
a series: R = 4-chlorobenzyl 
b series: R = cyclohexyl methyl
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A useful description of conformationally restricted diamines was outlined by 
Grygorenko and co-workers and is shown in Figure 4. The nitrogen atoms can be either 
primary or secondary amines and ideally will permit differential functionalization to 
provide structural diversity. The target compounds presented in this research (Figure 5) 
have amino groups which are part of the ring system, or endocyclic.^ Conformational 
restriction presents molecules with the nitrogen atoms in well-defined orientations with 
specific torsional angles and N-N distance. This can be helpful when these molecules are 
used to map a binding site on a protein. Functional groups attached via the nitrogen 
atoms can then be arrayed to explore defined regions of space.
Figure 4: Exocyclic (exo) amines are not part of the bicyclic scaffold. Endocyclic 
(endo) are involved in the bicyclic scaffold.[5]
S' /  NH2 ^NH Nl-U
[ bicyclic ] 
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Figure 5: [4.2.1 ]di-azabicyclic targets.
These structurally rigid, azabicyclic diamines have nitrogen atoms arrayed in a 
[4.2.1] framework which is rare and under-explored in the chemical literature.^ The
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target molecules presented are novel compounds that have not been previously reported 
in the chemical literature. The three target compounds are regioisomers that differ in the 
position of the nitrogen on the four atom bridge. The approach toward the scaffolds in 
this research is similar to the stereochemical diversity-oriented approach. Moving the 
nitrogen along the four atom bridge provides the opportunity to scan a broader region of 
space with structurally related ligands. This can provide useful structure-activity data for 
targets of choice. The reaction schemes for the three targets all originate from the same 
starting material. As outlined below, the synthesis begins with amino acid derivatives 
with defined absolute stereochemistry and will provide specific stereoisomers. Because 
the enantiomeric amino acid starting material is available and because the same synthetic 
pathways can be applied to furnish products, it will be possible to evaluate potential 
stereochemical effects on activity, selectivity and other properties. This paper describes 
the work done so far toward the synthesis of two (15, 16) of the [4.2.1]di-azabicyclic 
systems as well as characterization of novel intermediates.
The original retrosynthetic approach toward the target bicyclic diamines is 
outlined below (Scheme 1). These compounds can all be synthesized from an N- 
protected hydroxy proline (18) starting material. This route toward 15 and 16 was 
unsatisfactory due to of low yields and lack of stereospecificity in key reactions. As a 
result, our approach was modified as shown in Scheme 2.
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Scheme 1: Initial retrosynthetic approach toward [4.2.1] bicyclic scaffolds.
R2
Target 3
Ri
Our primary interest is in the synthesis of targets 15 and 16. Scheme 2 is a more 
promising approach as it utilizes selective reduction/oxidation and stereochemically well- 
defined reactions at key steps toward the final product. The three targets can all be 
synthesized from the same hydroxy proline derivative (18) mentioned above.
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Scheme 2: Modified retrosynthetic approach toward [4.2.1] bicyclic scaffolds.
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Results and Discussion
Scheme 3 outlines our initial approach toward 16. N-Boc-protected 2S, 4R 
hydroxy proline ester (18) was oxidized to the corresponding ketone (19) using potassium 
chlorochromate in DCM. This ketone underwent a Homer-Wadsworth-Emmons reaction 
with diethyl cyanomethylphosphonate and sodium hydride in THF to afford an E/Z 
mixture of the known a, (3 unsaturated nitrile, 20.[6] The nitrile (20) was then 
hydrogenated with a platinum catalyst in ethanol to get the amine (21) in 18% yield.[7] It 
was possible to isolate a single amine isomer, however it was not possible to determine 
the stereochemistry of the product because of our inability to identify diagnostic protons 
at 300 MHz. This sequence proved to be unsatisfactory for this reason as well as 
because of variability in the net yield for the oxidation-Homer-Wadsworth-Emmons- 
reduction sequence.
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Scheme 3: Initial synthetic scheme toward 16. (a) PCC, DCM (b) NaH, diethyl 
cyanomethylphosphonate, THF (c) H2, Pt(IV) oxide, EtOH.
Scheme 4 describes the forward reaction scheme toward 15. The synthesis begins 
with conversion of (18) to known mesylate, 23,[8] followed by Sn2 displacement using 
sodium azide in DMF to obtain known azide, 24.f9] The methyl ester was reduced 
chemoselectively using lithium borohydride in ether and methanol to get the known 
corresponding alcohol 25.[8] We observed that this solvent system provided a better yield 
and more rapid reaction compared to tetrahydrofuran as the sole solvent.[10] The alcohol 
in 25 was oxidized using pyridinium chlorochromate in DCM to furnish aldehyde 26 in 
58% yield. Wittig olefination using the protected acetaldehyde derivative (22) and 
potassium t-butoxide in THF afforded 27 in 84% yield as a mixture of geometric isomers 
that were not separated. 27 was reduced by catalytic hydrogenation in ethanol at room 
temperature to afford 28 in 87% yield. The amine was protected with CbzCl in THF to 
29 in 69% yield. Amine protection was carried out to facilitate isolation and 
characterization.
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Figure 6: (l,3-Dioxolan-2-ylmethyl)(triphenyl)phosphonium bromide
Scheme 4: Reaction scheme used toward the synthesis of 15. (d) MsCl, Et3N, DCM (e) 
NaN3, DMF, 90°C (f) LiBH4, Et20, MeOH, 0°C (g) PCC, DCM (h) t-BuOK, 22, THF (i) 
H2, Pd-C, EtOH G) NaHCOs, CbzCl, THF, H20  (k) IN HC1, THF (1) Toluenesulfonic 
acid, acetone, H20.
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Acetal cleavage was explored on a small scale to attempt to synthesize the 
hemiaminal 30 by stirring 28 in IN HC1 and THF. Unfortunately, the reaction was not 
successful and will require further investigation in the future. A similar reaction was 
carried out on the carboxybenzyl protected 29 with toluenesulfonic acid in acetone and 
water. Although there is no recorded yield, a product was isolated and analyzed by 'H 
and 13C NMR which can be found in the Spectral Analysis section (Figure 15 and Figure 
16). Based on this data, we propose the Cbz protected hemiaminal 31 structure. This 
assignment is supported by data in the literature J11] MS analysis of this product gave an 
m/z = 391. This mass is consistent with formation of a methoxy aminal (32) that forms 
on the HPLC column in acidic methanol. Additional analysis is required before we can 
confidently determine the structure of the molecule.
Figure 7: Proposed structure of methoxy aminal formed in HPLC column.
C b zN -^
Boc
32
The modified reaction scheme toward the target 16 is shown in Scheme 5. The 
synthesis begins with conversion of 18 to known tosylate (33)[12] followed by a Sn2 
displacement using sodium cyanide and DMSO to make known 34.[12] The methyl ester 
was chemoselectively reduced to the corresponding alcohol (35) using lithium 
borohydride in ether and methanol in a 65% yield. The alcohol was tosylated (36) in a 
77% yield and underwent Sn2 substitution in DMF to afford 37 in 81% yield. 37 was
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hydrolyzed with sodium hydroxide in water and ethanol to the carboxylic acid (38) in a 
75% yield.
Scheme 5: Reaction scheme used toward the synthesis of 16. (m) TsCl, DMAP, Et3N, 
DCM (n) NaCN, DMSO, 90°C (o) LiBH4, MeOH, Et20, 0°C (p) TsCl, DMAP, Et3N, 
DCM (q) NaN3, DMF, 90°C (r) NaOH, H20, EtOH, reflux.
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Experimental Section
Nuclear magnetic resonance spectra were recorded on Bruker Avance 300 FT- 
NMR Spectrometer. All samples were prepared in CDC13 unless stated otherwise and 
chemical shifts are reported in 5 values (ppm) relative to TMS. Mass spectrometry was 
obtained from a Shimadzu LCMS-2020.
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(19) -  18 (5.0 g, 20.4 mmol) and PCC (5.75 g, 26.7 mmol) were dissolved in DCM (200 
mL) and stirred overnight at room temperature. The reaction was filtered through celite 
then washed with IN HC1 (3 x 50 mL) and brine (35 mL). The organic layer was dried 
with Na2SC>4 and concentrated on rotary evaporator. The crude material was purified on 
an 80 g ISCO column (25% EtOAc -  hexanes) obtaining the 19 (3.0 g, 61%).[6]
(20) -  In anhydrous THF (6 mL) and NaH (40 mg of 60% oil dispersion, 1.7 mmol) was 
cooled to 0° C. Diethyl cyanomethylphosphonate (0.26 mL, 1.66 mmol) was added 
dropwise by syringe and stirred for 30 minutes at 0°C. A solution of 19 (500 mg, 2.1 
mmol) in THF (1 mL) was added then the reaction solution was warmed to room 
temperature and stirred overnight. Reaction was poured into EtOAc (50 mL) then 
washed with IN HC1 (2 x 10 mL) and brine (10 mL). Organic layer was dried with 
Na2S0 4  and concentrated on rotary evaporator. Crude material was purified on 12 g 
ISCO column (30% EtOAc -  hexanes) obtaining 20 (265 mg, 48.4%).[6]
(21) -  Solution of 20 (300 mg, 1.1 mmol) in ethanol (25 mL) was added to wet Pt(IV) 
Oxide (60 mg, 20% by weight) in Parr bottle. Reaction was hydrogenated at 35 psi 
overnight then filtered through celite and concentrated down. The crude compound was 
purified on 24 g ISCO column (10% MeOH -  DCM) obtaining the ethyl 21 (54 mg, 
18%)[7]
(23) -  18 (5.1 g, 21.1 mmol) was dissolved in DCM (100 mL) and Et3N (3.8 mL, 27.4 
mmol) and cooled to 0° C. Mesyl chloride (2.1g, 27.4 mmol) was added dropwise then 
warmed to room temperature and stirred overnight. Reaction was washed with IN HC1 
(3 x 25 mL) and washed with brine (1 x 25 mL), then dried with Na2S0 4  and
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concentrated on rotary evaporator. The crude product was purified on a 120 g ISCO 
column (50% ethyl acetate - hexanes) obtaining 23 (3.95 g, 58.0%).[8]
(24) -  23 (1.78 g, 5,5 mmol) and NaNs(0.93 g, 14.3 mmol) were dissolved in DMF (25 
mL), heated to 90° C and stirred overnight. Cooled to room temperature and poured into 
water (200 mL). Extracted with ethyl acetate (4 x 40 mL) and washed with brine (30 
mL). Organic layer was dried with Na2S04 and concentrated on rotary evaporator. 
Crude product was purified on 40 g ISCO column (30% ethyl acetate - hexanes) 
obtaining 24 (1.45 g, 97.7%).^
(25) -  Dry ether (25.0 mL) and methanol (0.84 mL) were added to LiBH4 (0.45 g, 20.7 
mmol) under N2 atmosphere. Mixture was cooled to 0° C and solution of 24 (4.0 g, 14.8 
mmol) in ether (25.0 mL) was added to dropwise and stirred for 2.5 h. Reaction was 
warmed to room temperature and poured into 150 mL diethyl ether. Washed with IN 
HC1 (3x35 mL) and brine (25 mL). Dried organic layer with Na2SC>4 and concentrated 
down on rotary evaporator. The crude material was purified on 40 g ISCO column (30% 
ethyl acetate -  hexanes) obtaining 25 (2.71 g, 75.7%).[8]
(26) -  Dissolved 25 (2.7 g, 11.2 mmol) and pyridinium chlorochromate (3.1 g, 14.5 
mmol) in dichloromethane (80 mL) and stirred at room temperature overnight. Reaction 
was filtered through celite and washed with IN HC1 (3 x 25 mL) and brine (25 mL). 
Organic layer was dried with Na2S04 and concentrated down on rotary evaporator. 
Crude material was purified on 40 g ISCO column (35% ethyl acetate -  hexanes) 
obtaining 26 (1.57 g, 58.5%). lU NMR (300 MHz, CDCb): 5 (ppm) = 9.649 -  9.526 
(1H, m), 4.284 -  4.152 (1H, m), 4.15 -  4.019 (1H, m), 3.64 -  3.45 (2H, m), 2.398 -  2.152
15
(2H, m), 1.45 (9H, s). 13C NMR (300 MHz, CDCls): 6 (ppm) = 201.83, 153.78, 81.32, 
81.04, 63.35, 63.22, 59.90, 59.03, 51.93, 51.65, 35.39, 33.93, 28.31. MS: m/z calcd for 
C10H16N4O3: 241.13 (M + H+), found 241.10.
(27) -  Dry THF (60 mL) was added to t-BuOK (0.93 g, 8.3 mmol) and 22 (3.7 g, 8.6 
mmol) and stirred at room temperature for 30 minutes. 26 (1.0 g, 4.2 mmol) was added 
and stirred for 1.5 h. Reaction was poured into water (200 mL) and extracted with ethyl 
acetate (3 x 50mL). Washed organic layer with brine, then dried with Na2SC>4 and 
concentrated on rotary evaporator. The crude material was purified on a 40 g IS CO 
column (25% ethyl acetate -  hexanes) obtaining the 27 (1.1 g, 84.5%). *H NMR (300 
MHz, CDCI3): 6 (ppm) = 6.048 -  5.868, 5.867 -  5.758 (1H, t), 5.709 -  5.419 (2H, m), 
5.363 -  5.232, 4.823 -  4.595 (1H, m), 4.235 -  4.09 (1H, m), 4.08 -  3.965 (2H, m), 3.964 
-  3.799 (2H, m), 3.758 -  3.599 (1H, m), 3.488 -  3.336 (1H, m), 2.512 -  2.325 (1H, m), 
1.958 -  1.848 (1H, m), 1.68 (1H, s), 1.44 (9H, s).
(28) -  Solution of 27 (160 mg, 0.5 mmol) in ethanol (10 mL) was added to wet 10% Pd-C 
(32 mg, 20% by weight) catalyst in Parr bottle. Reaction was hydrogenated at 35 PSI 
overnight then filtered through celite and concentrated on rotary evaporator. The crude 
material was purified on a 12 g ISCO column (5% methanol -  methylene chloride) 
obtaining the 28 (124 mg, 86.9%). lU NMR (300 MHz, CDCI3): 6 (ppm) = 4.909 -  
4.843 (1H, m), 4.015 -  3.927 (2H, m), 3.898 -  3.737 (4H, m), 3.488 -  3.348 (1H, m), 
2.931 -  2.828 (1H, m), 2.418 -  2.301 (1H, quint), 2.176 -  1.854 (4H, m), 1.682 -  1.59 
(3H, m), 1.45 (9H, s). 13C NMR (300 MHz, CDCI3): 6 (ppm) = 154.45, 104.38, 79.24, 
64.86, 64.80, 56.61, 54.64, 49.99, 40.90, 30.04, 29.65, 28.45
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(29) -  Dissolved 28 (487 mg, 1.7 mmol) and NaHCC>3 (285 mg, 3.4 mmol) in solution of 
THF (9 mL) and water (1 mL). Solution of CbzCl (0.3 mL, 2.0 mmol) in THF (2 mL) 
was added drop wise and stirred at room temperature 1 h. Reaction was poured into water 
(35 mL), then extracted with EtOAc (4 x 10 mL) and washed with brine (10 mL). 
Organic layer was dried with Na2S0 4  and concentrated on rotary evaporator. Crude 
material was purified on 12 g ISCO column (50% EtOAc -  hexanes) obtaining the 
protected 29 (496 mg, 69.4%). !H NMR (300 MHz, CDCb): 5 (ppm) = 7.434 -  7.309 
(5H, m), 5.171 -  4.965 (2H, m), 4.885 -  4.826 (1H, m), 4.231 -  4.04 (1H, m), 4.018 -  
3.746 (6H, m), 3.07 -  2.96 (1H, m), 2.468 -  2.336 (1H, m), 2.138 -  1.939 (1H, m), 1.711 
-  1.528 (4H, m), 1.45 (9H, s). 13C NMR (300 MHz, CDCb): 5 (ppm) = 155.82, 154.39, 
136.30, 128.59, 128.25, 128.19, 104.22, 79.59, 66.86, 64.94, 64.85, 56.09, 29.96, 28.47
(31) -  Added 29 (100 mg, 0.23 mmol) and tosylic acid (13 mg, 0.07 mmol) to acetone (3 
mL) and water (1 mL) solution and stirred at room temperature overnight. Poured into 
saturated NaHCCb (10 mL), extracted with EtOAc (4x10  mL), and washed with brine 
(10 mL). Organic layer was dried with Na2S0 4  and concentrated on rotary evaporator. 
Crude material was purified on 12 g ISCO column (50% EtOAc -  hexanes). *H NMR 
(300 MHz, CDCb): 6 (ppm) = 7.37 (5H, s), 6.831 -  6.611 (1H, m), 5.377 -  5.083 (3H, 
m), 4.745 -  4.554 (1H, m), 4.348 -  4.113 (1H, m), 3.768 -  3.54 (1H, m), 3.335 -  3.173 
(1H, t), 2.901 -  2.644 (1H, m), 2.439 -  2.233 (1H, m), 2.16 -  1.991 (1H, d), 1.917 -  
1.741 (1H, d), 1.587 -  1.396 (12H, m), 0.242 -  0.007 (s, silicon grease). 13C NMR (300 
MHz, CDCb): 5 (ppm) = 135.99, 128.63. 128.35, 128.16, 106.35, 79.44, 68.22, 28.53, 
1.04 (silicon grease). MS: m/z calcd for C21H31N2O5: 391.22 (M + H+), found 391.
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(33) -  18 (6.95 g 28.3 mmol), Et3N (5.1 mL, 36.8 mmol) and DMAP (0.86 g, 7.1 mmol) 
were dissolved in DCM (50 mL). Solution of tosyl chloride (7.0 g, 36.8 mmol) in DCM 
(50 mL) was added dropwise and stirred at room temperature overnight. Washed 
reaction with IN HC1 (3 x 20 mL) and brine (20 mL). Dried organic layer with Na2SC>4 
and concentrated down on rotary evaporator. The crude material was purified one 220 g 
ISCO column (30% ethyl acetate -  hexanes) obtaining 33 (8.4 g, 77.5%)J12^
(34) - 33 (1.93 g, 5.0 mmol) and NaCN (1.5 g, 30 mmol) were dissolved in DMSO (15 
mL) and stirred at 90° C for 1.5 h. Reaction was cooled to room temperature and poured 
into solution of saturated NaHCC>3 (25 mL) and water (25 mL). The mixture was 
extracted with ethyl acetate (4x15  mL) and the combined organic layers were washed 
with brine. Organic layer was dried with Na2S0 4  and concentrated down on rotary 
evaporator. The crude material was purified on a 40 g ISCO column (30% ethyl acetate -  
hexanes) obtaining the 34 (559 mg, 44.0%).[12]
(35) -  Dry Et20 (15 mL) was added to LiBLL (220 mg, 10.0 mmol) under argon 
atmosphere and cooled to 0°C. Solution of 34 (1.41 g, 5.6 mmol) dissolved in dry Et20 
(10 mL) and dry MeOH (0.4 mL, 10 mmol) was added dropwise and stirred at 0° C for 
3h. Reaction was warmed to room temperature and poured into Et20 (30 mL). Washed 
organic layer with saturated NH4CI (3 x 20mL), then dried with Na2SC>4 and concentrated 
on rotary evaporator. Crude material was purified on a 40 g ISCO column (40% ethyl 
acetate -  hexanes) obtaining 35 (0.82 g, 65.0%). !H NMR (300 MHz, CDCI3): 6 (ppm) = 
4.548 -  4.399, 4.091 -  3.881 (2H, m), 3.81 -  3.71 (2H, m), 3.543 -  3.445 (1H, m), 3.086 
-  2.939 (1H, quint), 2.552 -  2.418 (1H, quint), 2.018 -  1.877 (1H, m), 1.47 (9H, s). 13C
18
NMR (300 MHz, CDCh): 6 (ppm) = 119.39, 81.61, 66.29, 59.89, 50.02, 32.68, 29.73, 
28.36, 26.59.
(36) -  35 (0.82 g, 3.6 mmol), Et3N (0.7 mL, 5.0 mmol) and DMAP (0.1 g, 0.8 mmol) 
were dissolved in DCM (10 mL). Solution of tosyl chloride (1.3 g, 7.2 mmol) in DCM 
(10 mL) was added dropwise and stirred at room temperature overnight. Reaction was 
washed with IN HC1 (3 x 10 mL). Organic layer was dried with Na2S04 and 
concentrated on rotary evaporator. Crude product was purified on a 24 g ISCO column 
(40% ethyl acetate -  hexanes) obtaining 36 (1.05 g, 76.8%). !H NMR (300 MHz, 
CDC13): 6 (ppm) = 7.847 -  7.762 (2H, d), 7.421 -  7.318 (2H, d), 4.38 -  3.778 (5H, m), 
3.469 -  3.35 (1H, m), 3.065 -  2.923 (1H, quint), 2.511 -  2.416 (3H, m), 2.297 -  2.162 
(1H, m), 1.42 (9H, s). 13C NMR (300 MHz, CDCI3): 6 (ppm) = 145.61, 132.52, 130.73, 
128.08, 121.08, 80.23, 80.21, 55.35, 28.30, 21.62, 21.57, 21.55.
(37) -  36 (1.85 g, 4.9 mmol) and NaN3 (1.6 g, 25.5 mmol) were dissolved in DMF (10 
mL) and stirred at 90° C for 2.5 h. Cooled reaction to room temperature and poured into 
water (40 mL). Solution was extracted with ethyl acetate (3 x 10 mL). Organic layer 
was dried with Na2S04 and concentrated on rotary evaporator. The crude material was 
purified on a 24 g ISCO column (30% ethyl acetate -  hexanes) obtaining 37 (992 mg, 
80.7%). !H NMR (300 MHz, CDCI3): 6 (ppm) = 4.123 -  3.75 (2H, m), 3.722 -  3.538 
(1H, m), 3.503 -  3.348 (2H, m), 3.066 -  2.925 (1H, quint), 2.495 -  2.34 (1H, m), 2.298 -  
2.129 (1H, m), 1.44 (9H, s). m), 1.44 (9H, s). 13C NMR (300 MHz, CDCI3): 5 (ppm) = 
153.52, 119.77, 119.56, 81.01, 56.20, 55.60, 53.20, 51.87, 49.82, 33.42, 32.35, 28.34, 
26.96, 26.65, 26.16. MS: m/z calcd for C11H17N5O2: 252.14 (M + H+), found 252.21.
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(38) -  Solution of NaOH (140 mg, 3.5 mmol) and water (2 mL) were added to solution of 
37 (180 mg, 0.71 mmol) in ethanol (3 mL) and refluxed overnight. Reaction was cooled 
to room temperature and concentrated down on rotary evaporator. Added ice while 
adding IN HC1 to get solution to pH = 2.0, then saturated the solution with NaCl. The 
solution was extracted with ethyl acetate ( 3x10 mL). The organic layer was dried with 
Na2SC>4 and concentrated down on rotary evaporator. The crude material was purified on 
a 24 g ISCO column (5% methanol -  DCM) obtaining the 38 (143 mg, 74.7%). 1H NMR 
(300 MHz, CDCb): 5 (ppm) = 11.19 (1H, m), 4.22 -  3.89 (1H, m), 3.87 -  3.60 (2H, m), 
3.57 -  3.42(1H, m), 3.41 -  3.15 (2H, m), 2.48 -  2.06 (2H, m), 1.46 (9H, s). 13C NMR 
(300 MHz, CDCb): 5 (ppm) = 178.31, 154.37, 80.55, 56.60, 56.28, 53.81, 52.88, 49.03, 
41.68, 32.53, 31.70, 28.42. MS: m/z calcd for C11H13N4O4 269.13(M -  H+), found 
269.00.
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Spectral Analysis
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F ig u r e i l :  1H NMR of 28
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Figure 13: 1H NMR of 29
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Figure 15: XH NMR of 31
Figure 16: 13C N M R o f3 1
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Figure 17: XH NMR of 35
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Figure 19: 2H NMR of 36
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Figure 21: NMR of 37
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Figure 23: 1H NMR of 38
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